Q-omics provides the consensus-scored YEATS4 profile across patient tissues and cancer cell-line models. YEATS4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, YEATS4 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, YEATS4 protein abundance shows 32,807 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where YEATS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YEATS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YEATS4 survival associations across molecular data types. YEATS4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YEATS4 RNA expression–survival associations across cancer types. High YEATS4 expression shows unfavorable associations in KIRP, LUAD, LIHC and MESO, but favorable associations in UCEC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for YEATS4 RNA expression.
This table summarizes YEATS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for YEATS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YEATS4 shows lower tumor expression in THCA and higher tumor expression in BLCA, HNSC, LIHC, COAD and STAD. The BLCA box plot shows higher YEATS4 RNA expression in tumor versus normal tissue (log2 FC = +1.247, t-test p < 0.001).
This table shows molecular features associated with YEATS4 in patient tissues and cancer cell lines. In patient samples, YEATS4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, YEATS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
